Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Revenue (2020 - 2025)

Historic Revenue for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $6.8 million.

  • Vivos Therapeutics' Revenue rose 7572.54% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.3 million, marking a year-over-year increase of 1876.41%. This contributed to the annual value of $15.0 million for FY2024, which is 891.24% up from last year.
  • Latest data reveals that Vivos Therapeutics reported Revenue of $6.8 million as of Q3 2025, which was up 7572.54% from $3.8 million recorded in Q2 2025.
  • Vivos Therapeutics' 5-year Revenue high stood at $6.8 million for Q3 2025, and its period low was $3.0 million during Q1 2025.
  • Its 5-year average for Revenue is $4.0 million, with a median of $3.9 million in 2023.
  • As far as peak fluctuations go, Vivos Therapeutics' Revenue tumbled by 2225.62% in 2023, and later skyrocketed by 7572.54% in 2025.
  • Vivos Therapeutics' Revenue (Quarter) stood at $4.4 million in 2021, then decreased by 10.1% to $4.0 million in 2022, then dropped by 17.77% to $3.2 million in 2023, then increased by 13.85% to $3.7 million in 2024, then skyrocketed by 83.42% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $3.8 million for Q2 2025, and $3.0 million during Q1 2025.